At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 256 enrolled
Drug / intervention
Pemetrexed +2 moredrug
Likely dose
Pemetrexed 500 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer.
In Brief
A Phase 3 clinical trial evaluating Pemetrexed, Gemcitabine, and 1 other intervention for Non Small Cell Lung Cancer. Completed, enrolled 256 participants across 8 sites.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedNov 2009
Primary CompletionNov 2012
TodayJul 2026
First PostedNov 2, 2009
Enrollment StartNov 1, 2009
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.7 years ago
Interventions
Pemetrexeddrug
500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
Gemcitabinedrug
1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
Cisplatindrug
75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles